Better solution found for liver graft rejection
Print Edition
Chinese scientists have probably found a more effective solution to liver transplant rejection, which often prove fatal.
Liang Gaolin, head of a research team at the University of Science and Technology of China, has developed a new treatment for liver transplant rejection in collaboration with two other teams led by Wang Xuehao and Wang Fuqiang from Nanjing Medical University.
The findings, which were published in the latest issue of Advanced Materials, a Germany-based scientific journal, have been proved effective in rats, but are yet to be tested in clinical trials.
Rejection is the biggest problem of organ transplants. Immune suppressive drugs such as tacrolimus are directly administered to patients after their surgery for T-cell inhibition.
However, direct oral administration of tacrolimus can result in severe side effects.
Cell experiments on rats have shown that tacrolimus encapsulated in two hydrogels when applied to the scar surface of the transplant has a better inhibition effect on the activated T-cells than free drug tacrolimus.
Liver transplant experiments indicate that, with the same dose of tacrolimus, rat recipients in the gel group showed a significantly extended median survival time of 22 days, while the rats treated with conventional tacrolimus medication only had a median survival time of 13 days.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
